Ariadne’s PathwayStudio(R) 4.0 Achieves GeneChip-compatible(TM) Status with the Affymetrix GeneChip(R) Microarray Platform
Ariadne Genomics, Inc. today announced that it has joined the Affymetrix GeneChip-compatible Applications Program, which provides customers with a broad spectrum of software solutions for biomedical research and development. Ariadne’s PathwayStudio® 4.0 pathway analysis software has earned GeneChip-compatible™ status. As a GeneChip-compatible software provider, Ariadne is committed to seamlessly integrating their entire pathway analysis product pipeline with the Affymetrix GeneChip technology.
PathwayStudio 4.0 (formerly marketed as PathwayAssist) allows life scientists to analyze and interpret gene expression microarray data in the context of biological pathways and to reconstruct regulatory networks from gene expression experiments. The software comes with a database of over 1,000,000 molecular interaction facts extracted from the scientific literature and over 1,000 reconstructed pathways.
“We are delighted that PathwayStudio 4.0 has achieved GeneChip-compatible status with Affymetrix,” said Dr. Ilya Mazo, president of Ariadne. “Ariadne’s mission is to provide life scientists with tools and solutions to stimulate biomedical research and drug development. The integration between PathwayStudio and the Affymetrix GeneChip microarray platform is yet another vital milestone in the realization of our goal.”
“Pathway-level annotation and functional analysis is fast becoming a standard part of gene expression microarray data analysis,” said Steve Lincoln, vice president of Informatics at Affymetrix. “The integration between the Affymetrix GeneChip platform and Ariadne’s PathwayStudio allows our mutual customers to extract the greatest value from their microarray data.”
PathwayStudio is available as a desktop or client-server solution. A 20 day fully functional trial can be found on the Ariadne website.
About the Affymetrix Developers Network (ADN)
Through one of the largest third-party software developer communities within the life science industry, Affymetrix (Nasdaq: AFFX) works with its collaborators to provide a broad spectrum of solutions for leveraging gene expression and genetic variation analysis in both biomedical research and development. Membership in ADN is free of charge for both commercial and academic software developers. For more information please visit www.affymetrix.com/genechip/developer or browse the GeneChip-compatible Software Solutions Catalog at www.affymetrix.com/genechip/compatible.
About Affymetrix
Affymetrix scientists invented the world’s first microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip® technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world’s top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,400 systems have been shipped around the world and more than 4,000 peer-reviewed papers have been published using the technology. Affymetrix’ patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyze the relationship between genetics and health. Headquartered in Santa Clara, Calif., Affymetrix has subsidiaries in Europe and Asia in addition to manufacturing facilities in Sacramento, Calif. and Bedford, Mass. The company has about 1,000 employees worldwide. For more information about Affymetrix, please visit the company’s website at www.Affymetrix.com .
About Ariadne Genomics
Ariadne develops systems biology software for life science research. Products include PathwayStudio® (formerly PathwayAssist) leading pathway analysis software and PathwayExpert™ informatics platform for the research of cellular regulation and drug response modeling. Ariadne software is equipped with MedScan™, a mature information extraction technology based on domain-specific natural language processing (NLP), and includes a ResNet™ family of automatically generated and manually curated molecular network databases. Ariadne’s MedScan Reader™ is a biomedical literature browser that greatly facilitates the reading of scientific text by automatically extracting and displaying the information of interest.
www.ariadnegenomics.com
